Table 1.
SF-36: assessment of instrument properties in SLE
| Author, year | Description of study | Reliability validity | Responsiveness and ability to detect change | MCID/ MID | |||
| Internal consistency | Test-retest | Construct | Known groups | ||||
| Baba et al, 2018 20 |
Prospective study in Japanese patients with SLE (n=233). SF-36 completed at baseline and 1 year follow-up | ✓ | ✓ | ✓ | ✓ | ||
| Furie et al 2014 35 |
Secondary analysis of pooled data from the BLISS Trials in patients with SLE (n=1684). Changes in clinical and HRQoL measures from baseline to week 52 were compared between SRI responders and non-responders | ✓ | |||||
| Nantes et al 2018 22 |
Prospective study in patients with SLE (n=78). SF-36 and LupusQoL completed at baseline and follow-up | ✓ | |||||
| McElhone et al 2016 23 |
Prospective, longitudinal study in patients with SLE (n=101) experiencing a flare. SF-36 completed every 4 weeks for 9 months | ✓ | ✓ | ✓ | |||
| Devilliers et al 2015 29 |
Prospective study in 185 patients with SLE (n=185). SF-36 completed monthly for 3 months | ✓ | ✓ | ||||
| Yilmaz- Oner et al, 2016 24 |
Cross-sectional study in Turkish patients (n=113) with SLE. SF-36 and LupusQoL completed once during a single visit | ✓ | |||||
| Garcia- Carrasco et al, 2012 25 |
Cross-sectional study in women with SLE (n=127). SF- 36 and LupusQoL completed once during study initiation | ✓ | |||||
| Hanly et al, 2011 28 |
Prospective international study (n=274) to evaluate change in HRQoL in association with neuropsychiatric events in newly diagnosed patients with SLE | ✓ | ✓ | ||||
| Touma et al, 2011 27 |
Longitudinal study in SLE (n=41). SF-36 and LupusQoL completed monthly for 12 months | ✓ | ✓ | ||||
| Wolfe et al, 2010 26 |
Longitudinal study in SLE (n=1316). Patients followed semi-annually for 10 years. A single random observation from each patient was included in analysis for SF-36 and EQ-5D | ✓ | |||||
| Colangelo et al, 2009 30 |
Prospective study in patients with SLE (n=202). SF-36 completed at two consecutive visits annually | ✓ | |||||
| Strand et al, 2005 31 |
Post hoc analysis of 2 clinical trials of abetimus sodium (n=298, phase III; n=189, phase II/III). SF-36 completed at 6 months and 12 months; responders and non- responders were identified from each trial | ✓ | |||||
| Thumboo et al, 2000 21 |
Cross-sectional study in Chinese patients with SLE (n=69), Chinese version of SF-36 completed twice within 7–14 days | ✓ | ✓ | ✓ | |||
| Thumboo et al, 1999 19 |
Cross-sectional study in Asian patients with SLE (n=118). SF-36 completed twice within a 14-day period | ✓ | ✓ | ✓ | |||
✓=Instrument property assessed in study.
EQ-5D, EuroQol Five-Dimensional Questionnaire; HRQoL, health-related quality of life; LupusQoL, Lupus Quality of Life questionnaire; MCID, minimum clinically important difference; MID, minimum important difference; SF-36, 36 Item Health Survey-Short Form; SRI, SLE Responder Index.